Your Shopping Cart Is Empty
| Report Code: A05923 | Jan 2020 | Pages: 165 | ||
| Tables: 111 | Charts: 42 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Immunosuppressants Market
Request Now !The global immunosuppressants market size was valued at $13,890.0 million in 2018 and is expected to reach $42,511.37 million by 2026, registering a CAGR of 14.7% from 2019 to 2026. Immunosuppressants belong to the drug family that helps in suppressing the immune response or agents. During organ transplantation, from a donor to a recipient, immune system of the recipient gets stimulated and thus, produces immune response like it does in response to other foreign material. This immune response causes serious damage to the transplanted or grafted organ. It is often called as rejection, which can be acute or chronic. This organ rejection is prohibited by using immunosuppressive drugs, which block the immune response and protect new organ and its function. They are mainly used to avert several autoimmune diseases including myasthenia gravis, arthritis, lupus, rheumatoid arthritis, Crohn’s disease, and organ transplant rejections such as transplant of kidney, liver, and heart. There are three stages of clinical immunosuppression: induction therapy, maintenance therapy, and treatment of an established acute rejection response.
Surge in prevalence of autoimmune disorders such as arthritis, multiple sclerosis, and alopecia areata is the major factor that drives the immunosuppressants market growth. In addition, surge in organ transplant procedures such as kidney transplant and liver transplant due to rise in incidences of organ failure further propel the growth of immunosuppressant market. For instance, according to the U.S. National Kidney Association, in 2014, 17,107 kidney transplants took place in the US. In addition, as per the U.S. Government Information on Organ Donation and Transplantation, 36,528 organ transplants were performed in 2018 in the country. However, dearth of availability of organ donors and high cost of these drugs are the limitations for the growth of this immunosuppressant market. For instance, as per the U.S. Government Information on Organ Donation and Transplantation, more than 113,000 number of individuals are on the national transplant waiting list as of July 2019. On the contrary, increase in use of tissue engineering for generation of implants provide growth opportunities for the market. In addition, rise in disposable income in developing economies and surge in awareness among individuals toward organ donation is anticipated to create lucrative opportunities for the market in the near future.
Global Immunosuppressant Market Segmentation:
The immunosuppressants market is segmented on the basis of drug class, indication, distribution channel, and region. By drug class, it is divided into corticosteroids, monoclonal antibodies, calcineurin inhibitors, mTOR inhibitors, anti-proliferative agents, and others. On the basis of indication, it is categorized into organ transplantation, autoimmune disorders, and non-autoimmune inflammatory diseases. By distribution channel, it is classified into hospital pharmacies, retail pharmacies, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Drug class segment review
By drug class, the calcineurin inhibitors segment accounted for majority of the immunosuppressants market share in 2018 and is expected to exhibit a prominent growth rate in the near future, owing to the fact that it is the most used immunosuppressant drug used after organ transplantation to suppress hyper immune response. The most widely prescribed calcineurin inhibitor drugs include cyclosporine and tacrolimus. This segment is also anticipated to be the fastest growing drug class segment during the forecast period.
Indication segment review
Based on immunosuppressants market analysis, the auto-immune disorder segment dominated the immunosuppressants market in 2018, and is anticipated to maintain its dominance during the forecast period. This is attributed to the surge incidence of auto immune disorders across the globe. For instance, according to the U.S. National Institute of Environmental Health Sciences (NIH), autoimmune diseases are among the most prevalent diseases in the country affecting more than 23.5 million Americans.
By region, North America accounted for majority of the market share in 2018, and is anticipated to continue this trend during the forecast period. This is attributed to the increase in prevalence of auto-immune disorders in this region. Moreover, organ failure incidences are also on the rise in this region, including kidney failure and liver failure. However, the Asia-Pacific region is anticipated to grow at the fastest rate during the forecast period. This is attributed to the surge in awareness among individuals toward organ donation. Further, rise in healthcare expenditure, growth in disposable incomes, and government measures toward making immunosuppressant drugs available for patients contribute to the market growth.
Comprehensive competitive analysis and profiles of major immunosuppressant market players such as Astellas Pharma, Inc., Bristol Myers Squibb, F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc., Intas Pharmaceuticals Ltd., Johnson & Johnson, Mylan Laboratories Inc., Novartis AG, Pfizer, Inc., and Sanofi S.A are provided in this report.
Immunosuppressants Market Report Highlights
| Aspects | Details |
|---|---|
| By Indication |
|
| By Drug Class |
|
| By Distribution Channel |
|
| By Region |
|
| Key Market Players | GlaxoSmithKline Plc., Pfizer Inc., AbbVie Inc., Astellas Pharma Inc., Johnson & Johnson (Janssen Pharmaceuticals, Inc.), Novartis International AG (Sandoz), Mylan N.V., Bristol-Myers Squibb Company, Sanofi S.A., INTAS PHARMACEUTICALS LTD. (Accord Healthcare Ltd.) |
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Moderate bargaining power of buyers
3.3.2. Low bargaining power of suppliers
3.3.3. Moderate threat of substitutes
3.3.4. Low threat of new entrants
3.3.5. Moderate competitive rivalry
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Surge in autoimmune disorders
3.5.1.2. Increase in demand for organ transplantation
3.5.2. Restraint
3.5.2.1. Lack of awareness towards organ transplantation
3.5.3. Opportunity
3.5.3.1. Various growth opportunities in emerging economies
CHAPTER 4: IMMUNOSUPPRESSANT MARKET, BY INDICATION
4.1. Overview
4.1.1. Market size and forecast
4.2. Organ Transplantation
4.2.1. Key market trends and opportunities
4.2.2. Market size and forecast
4.2.3. Market share analysis, by country
4.3. Autoimmune Disorders
4.3.1. Key market trends and growth opportunities
4.3.2. Market size and forecast
4.3.3. Market share analysis, by country
4.4. Other Diseases
4.4.1. Key market trends and opportunities
4.4.2. Market size and forecast
4.4.3. Market share analysis, by country
CHAPTER 5: IMMUNOSUPPRESSANT MARKET, BY DRUG CLASS
5.1. Overview
5.1.1. Market size and forecast
5.2. Calcineurin Inhibitors
5.2.1. Market size and forecast
5.2.2. Market share analysis, by country
5.3. Corticosteroids
5.3.1. Market size and forecast
5.3.2. Market share analysis, by country
5.4. Monoclonal Antibodies (mAbs)
5.4.1. Market size and forecast
5.4.2. Market share analysis, by country
5.5. mTOR Inhibitors
5.5.1. Market size and forecast
5.5.2. Market share analysis, by country
5.6. Other Immunosuppressants
5.6.1. Market size and forecast
5.6.2. Market share analysis, by country
CHAPTER 6: IMMUNOSUPPRESSANTS MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital pharmacies
6.2.1. Market size and forecast
6.2.2. Market share analysis, by country
6.3. Retail pharmacies
6.3.1. Market size and forecast
6.3.2. Market share analysis, by country
6.4. Online pharmacy
6.4.1. Market size and forecast
6.4.2. Market share analysis, by country
CHAPTER 7: IMMUNOSUPPRESSANT MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends and opportunities
7.2.2. Market size and forecast, by country
7.2.3. Market size and forecast, by indication
7.2.4. Market size and forecast, by drug class
7.2.5. Market size and forecast, by distribution channel
7.2.6. U.S.
7.2.6.1. U.S. market size and forecast, by indication
7.2.6.2. U.S. market size and forecast, by drug class
7.2.6.3. U.S. market size and forecast, by distribution channel
7.2.7. Canada
7.2.7.1. Canada market size and forecast, by indication
7.2.7.2. Canada market size and forecast, by drug class
7.2.7.3. Canada market size and forecast, by distribution channel
7.2.8. Mexico
7.2.8.1. Mexico market size and forecast, by indication
7.2.8.2. Mexico market size and forecast, by drug class
7.2.8.3. Mexico market size and forecast, by distribution channel
7.3. Europe
7.3.1. Key growth factors and opportunities
7.3.2. Market size and forecast, by country
7.3.3. Market size and forecast, by indication
7.3.4. Market size and forecast, by drug class
7.3.5. Market size and forecast, by distribution channel
7.3.6. Germany
7.3.6.1. Germany market size and forecast, by indication
7.3.6.2. Germany market size and forecast, by drug class
7.3.6.3. Germany market size and forecast, by distribution channel
7.3.7. France
7.3.7.1. France market size and forecast, by indication
7.3.7.2. France market size and forecast, by drug class
7.3.7.3. France market size and forecast, by distribution channel
7.3.8. UK
7.3.8.1. UK market size and forecast, by indication
7.3.8.2. UK market size and forecast, by drug class
7.3.8.3. UK market size and forecast, by distribution channel
7.3.9. Italy
7.3.9.1. Italy market size and forecast, by indication
7.3.9.2. Italy market size and forecast, by drug class
7.3.9.3. Italy market size and forecast, by distribution channel
7.3.10. Rest of Europe
7.3.10.1. Rest of Europe market size and forecast, by indication
7.3.10.2. Rest of Europe market size and forecast, by drug class
7.3.10.3. Rest of Europe market size and forecast, by distribution channel
7.4. Asia-Pacific
7.4.1. Key growth factors and opportunities.
7.4.2. Market size and forecast, by country
7.4.3. Market size and forecast, by indication
7.4.4. Market size and forecast, by drug class
7.4.5. Market size and forecast, by distribution channel
7.4.6. Japan
7.4.6.1. Japan market size and forecast, by indication
7.4.6.2. Japan market size and forecast, by drug class
7.4.6.3. Japan market size and forecast, by distribution channel
7.4.7. China
7.4.7.1. China market size and forecast, by indication
7.4.7.2. China market size and forecast, by drug class
7.4.7.3. China market size and forecast, by distribution channel
7.4.8. India
7.4.8.1. India market size and forecast, by indication
7.4.8.2. India market size and forecast, by drug class
7.4.8.3. India market size and forecast, by distribution channel
7.4.9. Australia
7.4.9.1. Australia market size and forecast by indication
7.4.9.2. Australia market size and forecast, by drug class
7.4.9.3. Australia market size and forecast, by distribution channel
7.4.10. Rest of Asia-Pacific
7.4.10.1. Rest of Asia-Pacific market size and forecast by indication
7.4.10.2. Rest of Asia-Pacific market size and forecast, by drug class
7.4.10.3. Rest of Asia-Pacific market size and forecast, by distribution channel
7.5. LAMEA
7.5.1. Key growth factors and opportunities
7.5.2. Market size and forecast, by country
7.5.3. Market size and forecast, by indication
7.5.4. Market size and forecast, by drug class
7.5.5. Market size and forecast, by distribution channel
7.5.6. Brazil
7.5.6.1. Brazil market size and forecast, by indication
7.5.6.2. Brazil market size and forecast, by drug class
7.5.6.3. Brazil market size and forecast, by distribution channel
7.5.7. Saudi Arabia
7.5.7.1. Saudi Arabia market size and forecast, by indication
7.5.7.2. Saudi Arabia market size and forecast, by drug class
7.5.7.3. Saudi Arabia market size and forecast, by distribution channel
7.5.8. South Africa
7.5.8.1. South Africa market size and forecast, by indication
7.5.8.2. South Africa market size and forecast, by drug class
7.5.8.3. South Africa market size and forecast, by distribution channel
7.5.9. Rest of LAMEA
7.5.9.1. Rest of LAMEA market size and forecast, by indication
7.5.9.2. Rest of LAMEA market size and forecast, by drug class
7.5.9.3. Rest of LAMEA market size and forecast, by distribution channel
CHAPTER 8: COMPANY PROFILES
8.1. AbbVie Inc.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product Portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. Astellas Pharma Inc.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product Portfolio
8.2.5. Business performance
8.3. Bristol-Myers Squibb Company
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments
8.4. GlaxoSmithKline Plc.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.4.6. Key strategic moves and developments
8.5. INTAS PHARMACEUTICALS LTD. (Accord Healthcare Ltd.)
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.6. Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments
8.7. Mylan N.V.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments
8.8. Novartis International AG (Sandoz)
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments
8.9. Pfizer Inc.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments
8.10. Sanofi S.A.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
8.10.6. Key strategic moves and developments
LIST OF TABLES
TABLE 01. IMMUNOSUPPRESSANT MARKET, BY INDICATION, 2018-2026 ($MILLION)
TABLE 02. IMMUNOSUPPRESANTS MARKET FOR ORGAN TRANSPLANTATION MARKET, BY REGION, 2018-2026 ($MILLION)
TABLE 03. IMMUNOSUPPRESSANT MARKET FOR AUTOIMMUNE DISORDERS, BY REGION, 2018-2026 ($MILLION)
TABLE 04. IMMUNOSUPPRESSANTS MARKET FOR OTHERS, BY REGION, 2018-2026 ($MILLION)
TABLE 05. IMMUNOSUPPRESSANT MARKET, BY DRUG CLASS, 2018-2026 ($MILLION)
TABLE 06. CALCINEURIN INHIBITORS IMMUNOSUPPRESSANT MARKET, BY REGION, 2018-2026 ($MILLION)
TABLE 07. IMMUNOSUPPRESSANT CORTICOSTEROIDSS MARKET, BY REGION, 2018-2026 ($MILLION)
TABLE 08. MONOCLONAL ANTIBODIES IMMUNOSUPPRESSANT MARKET, BY REGION, 2018-2026 ($MILLION)
TABLE 09. MTOR INHIBITORS IMMUNOSUPPRESSANT MARKET, BY REGION, 2018-2026 ($MILLION)
TABLE 10. OTHER IMMUNOSUPPRESSANT MARKET, BY REGION, 2018-2026 ($MILLION)
TABLE 11. IMMUNOSUPPRESSANT MARKET, BY DISTRIBUTION CHANNEL, 2018-2026 ($MILLION)
TABLE 12. IMMUNOSUPPRESSANT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2018-2026 ($MILLION)
TABLE 13. IMMUNOSUPPRESSANT CORTICOSTEROIDSS MARKET FOR RETAIL PHARMACIES, BY REGION, 2018-2026 ($MILLION)
TABLE 14. IMMUNOSUPPRESSANT MARKET FOR ONLINE PHARMACY, BY REGION, 2018-2026 ($MILLION)
TABLE 15. IMMUNOSUPPRESSANT MARKET, BY REGION, 2018-2026 ($MILLION)
TABLE 16. NORTH AMERICA IMMUNOSUPPRESSANT MARKET, BY COUNTRY, 2018-2026 ($MILLION)
TABLE 17. NORTH AMERICA IMMUNOSUPPRESSANT MARKET, BY INDICATION, 2018-2026 ($MILLION)
TABLE 18. NORTH AMERICA IMMUNOSUPPRESSANT MARKET, BY DRUG CLASS, 2018–2026 ($MILLION)
TABLE 19. NORTH AMERICA IMMUNOSUPPRESSANT MARKET, BY DISTRIBUTION CAHNNEL, 2018-2026 ($MILLION)
TABLE 20. U.S. IMMUNOSUPPRESSANT MARKET BY INDICATION, 2018-2026 ($MILLION)
TABLE 21. U.S. IMMUNOSUPPRESSANT MARKET BY DRUG CLASS, 2018-2026 ($MILLION)
TABLE 22. U.S. IMMUNOSUPPRESSANT MARKET BY DISTRIBUTION CHANNEL, 2018-2026 ($MILLION)
TABLE 23. CANADA IMMUNOSUPPRESSANT MARKET BY INDICATION, 2018-2026 ($MILLION)
TABLE 24. CANADA IMMUNOSUPPRESSANT MARKET BY DRUG CLASS, 2018-2026 ($MILLION)
TABLE 25. CANADA IMMUNOSUPPRESSANT MARKET BY DISTRIBUTION CHANNEL, 2018-2026 ($MILLION)
TABLE 26. MEXICO IMMUNOSUPPRESSANT MARKET, BY INDICATION, 2018-2026 ($MILLION)
TABLE 27. MEXICO IMMUNOSUPPRESSANT MARKET, BY DRUG CLASS, 2018-2026 ($MILLION)
TABLE 28. MEXICO IMMUNOSUPPRESSANT MARKET, BY DISTRIBUTION CHANNEL, 2018-2026 ($MILLION)
TABLE 29. EUROPE IMMUNOSUPPRESSANT MARKET, BY COUNTRY, 2018-2026 ($MILLION)
TABLE 30. EUROPE IMMUNOSUPPRESSANT MARKET, BY INDICATION, 2018-2026 ($MILLION)
TABLE 31. EUROPE IMMUNOSUPPRESSANT MARKET, BY DRUG CLASS, 2018–2026 ($MILLION),
TABLE 32. EUROPE IMMUNOSUPPRESSANT MARKET, BY DISTRIBUTION CHANNEL, 2018-2026 ($MILLION)
TABLE 33. GERMANY IMMUNOSUPPRESSANT MARKET, BY INDICATION, 2018-2026 ($MILLION)
TABLE 34. GERMANY IMMUNOSUPPRESSANT MARKET, BY DRUG CLASS, 2018-2026 ($MILLION)
TABLE 35. GERMANY IMMUNOSUPPRESSANT MARKET, BY DISTRIBUTION CHANNEL, 2018-2026 ($MILLION)
TABLE 36. FRANCE IMMUNOSUPPRESSANT MARKET, BY INDICATION, 2018-2026 ($MILLION)
TABLE 37. FRANCE IMMUNOSUPPRESSANT MARKET, BY DRUG CLASS, 2018-2026 ($MILLION)
TABLE 38. FRANCE IMMUNOSUPPRESSANT MARKET, BY DISTRIBUTION CHANNEL, 2018-2026 ($MILLION)
TABLE 39. U.K. IMMUNOSUPPRESSANT MARKET, BY INDICATION, 2018-2026 ($MILLION)
TABLE 40. U.K. IMMUNOSUPPRESSANT MARKET, BY DRUG CLASS, 2018-2026 ($MILLION)
TABLE 41. U.K. IMMUNOSUPPRESSANT MARKET, BY DISTRIBUTION CHANNEL, 2018-2026 ($MILLION)
TABLE 42. ITALY IMMUNOSUPPRESSANT MARKET, BY INDICATION, 2018-2026 ($MILLION)
TABLE 43. ITALY IMMUNOSUPPRESSANT MARKET, BY DRUG CLASS, 2018-2026 ($MILLION)
TABLE 44. ITALY IMMUNOSUPPRESSANT MARKET, BY DISTRIBUTION CHANNEL, 2018-2026 ($MILLION)
TABLE 45. REST OF EUROPE IMMUNOSUPPRESSANT MARKET, BY INDICATION, 2018-2026 ($MILLION)
TABLE 46. REST OF EUROPE IMMUNOSUPPRESSANT MARKET, BY DRUG CLASS, 2018-2026 ($MILLION)
TABLE 47. REST OF EUROPE IMMUNOSUPPRESSANT MARKET, BY DISTRIBUTION CHANNEL, 2018-2026 ($MILLION)
TABLE 48. ASIA-PACIFIC IMMUNOSUPPRESSANT MARKET, BY COUNTRY, 2018-2026 ($MILLION)
TABLE 49. ASIA-PACIFIC IMMUNOSUPPRESSANT MARKET, BY INDICATION, 2018-2026 ($MILLION)
TABLE 50. ASIA-PACIFIC IMMUNOSUPPRESSANT MARKET, BY DRUG CLASS, 2018–2026 ($MILLION),
TABLE 51. ASIA-PACIFIC IMMUNOSUPPRESSANT MARKET, BY DISTRIBUTION CHANNEL, 2018-2026 ($MILLION)
TABLE 52. JAPAN IMMUNOSUPPRESSANT MARKET, BY INDICATION, 2018-2026 ($MILLION)
TABLE 53. JAPAN IMMUNOSUPPRESSANT MARKET, BY DRUG CLASS, 2018-2026 ($MILLION)
TABLE 54. JAPAN IMMUNOSUPPRESSANT MARKET, BY DISTRIBUTION CHANNEL, 2018-2026 ($MILLION)
TABLE 55. CHINA IMMUNOSUPPRESSANT MARKET, BY INDICATION, 2018-2026 ($MILLION)
TABLE 56. CHINA IMMUNOSUPPRESSANT MARKET, BY DRUG CLASS, 2018-2026 ($MILLION)
TABLE 57. CHINA IMMUNOSUPPRESSANT MARKET, BY DISTRIBUTION CHANNEL, 2018-2026 ($MILLION)
TABLE 58. INDIA IMMUNOSUPPRESSANT MARKET, BY INDICATION, 2018-2026 ($MILLION)
TABLE 59. INDIA IMMUNOSUPPRESSANT MARKET, BY DRUG CLASS, 2018-2026 ($MILLION)
TABLE 60. INDIA IMMUNOSUPPRESSANT MARKET, BY DISTRIBUTION CHANNEL, 2018-2026 ($MILLION)
TABLE 61. AUSTRALIA IMMUNOSUPPRESSANT MARKET, BY INDICATION, 2018-2026 ($MILLION)
TABLE 62. AUSTRALIA IMMUNOSUPPRESSANT MARKET, BY DRUG CLASS, 2018-2026 ($MILLION)
TABLE 63. AUSTRALIA IMMUNOSUPPRESSANT MARKET, BY DISTRIBUTION CHANNEL, 2018-2026 ($MILLION)
TABLE 64. REST OF ASIA-PACIFIC IMMUNOSUPPRESSANT MARKET, BY INDICATION, 2018-2026 ($MILLION)
TABLE 65. REST OF ASIA-PACIFIC IMMUNOSUPPRESSANT MARKET, BY DRUG CLASS, 2018-2026 ($MILLION)
TABLE 66. REST OF ASIA-PACIFIC IMMUNOSUPPRESSANT MARKET, BY DISTRIBUTION CHANNEL, 2018-2026 ($MILLION)
TABLE 67. LAMEA IMMUNOSUPPRESSANT MARKET, BY COUNTRY, 2018-2026 ($MILLION)
TABLE 68. LAMEA IMMUNOSUPPRESSANT MARKET, BY INDICATION, 2018-2026 ($MILLION)
TABLE 69. LAMEA IMMUNOSUPPRESSANT MARKET, BY DRUG CLASS, 2018–2026 ($MILLION),
TABLE 70. LAMEA IMMUNOSUPPRESSANT MARKET, BY DISTRIBUTION CHANNEL, 2018-2026 ($MILLION)
TABLE 71. BRAZIL IMMUNOSUPPRESSANT MARKET, BY INDICATION, 2018-2026 ($MILLION)
TABLE 72. BRAZIL IMMUNOSUPPRESSANT MARKET, BY DRUG CLASS, 2018-2026 ($MILLION)
TABLE 73. BRAZIL IMMUNOSUPPRESSANT MARKET, BY DISTRIBUTION CHANNEL, 2018-2026 ($MILLION)
TABLE 74. SAUDI ARABIA IMMUNOSUPPRESSANT MARKET, BY INDICATION, 2018-2026 ($MILLION)
TABLE 75. SAUDI ARABIA IMMUNOSUPPRESSANT MARKET, BY DRUG CLASS, 2018-2026 ($MILLION)
TABLE 76. SAUDI ARABIA IMMUNOSUPPRESSANT MARKET, BY DISTRIBUTION CHANNEL, 2018-2026 ($MILLION)
TABLE 77. SOUTH AFRICA IMMUNOSUPPRESSANT MARKET, BY INDICATION, 2018-2026 ($MILLION)
TABLE 78. SOUTH AFRICA IMMUNOSUPPRESSANT MARKET, BY DRUG CLASS, 2018-2026 ($MILLION)
TABLE 79. SOUTH AFRICA IMMUNOSUPPRESSANT MARKET, BY DISTRIBUTION CHANNEL, 2018-2026 ($MILLION)
TABLE 80. REST OF LAMEA IMMUNOSUPPRESSANT MARKET, BY INDICATION, 2018-2026 ($MILLION)
TABLE 81. REST OF LAMEA IMMUNOSUPPRESSANT MARKET, BY DRUG CLASS, 2018-2026 ($MILLION)
TABLE 82. REST OF LAMEA IMMUNOSUPPRESSANT MARKET, BY DISTRIBUTION CHANNEL, 2018-2026 ($MILLION)
TABLE 83. ABBVIE: COMPANY SNAPSHOT
TABLE 84. ABBVIE: OPERATING SEGMENTS
TABLE 85. ABBOTT: PRODUCT PORTFOLIO
TABLE 86. ASTELLAS: COMPANY SNAPSHOT
TABLE 87. ASTELLAS: PRODUCTS AND SERVICES
TABLE 88. ASTELLAS: PRODUCT PORTFOLIO
TABLE 89. BMS: COMPANY SNAPSHOT
TABLE 90. BMS: PRODUCT PORTFOLIO
TABLE 91. GSK: COMPANY SNAPSHOT
TABLE 92. GSK: OPERATING SEGMENTS
TABLE 93. GSK: PRODUCT PORTFOLIO
TABLE 94. INTAS: COMPANY SNAPSHOT
TABLE 95. INTAS: PRODUCT PORTFOLIO
TABLE 96. J&J: COMPANY SNAPSHOT
TABLE 97. J&J: OPERATING SEGMENTS
TABLE 98. J&J: PRODUCT PORTFOLIO
TABLE 99. MYLAN: COMPANY SNAPSHOT
TABLE 100. MYLAN: OPERATING SEGMENTS
TABLE 101. MYLAN: PRODUCT PORTFOLIO
TABLE 102. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 103. NOVARTIS: OPERATING SEGMENTS
TABLE 104. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 105. PFIZER: COMPANY SNAPSHOT
TABLE 106. PFIZER: OPERATING SEGMENTS
TABLE 107. PFIZER: PRODUCT PORTFOLIO
TABLE 108. SANOFI: COMPANY SNAPSHOT
TABLE 109. SANOFI: OPERATING SEGMENTS
TABLE 110. SANOFI: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. IMMUNOSUPPRESSANT, MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP PLAYER POSITIONING
FIGURE 04. DRIVERS, RESTRAINT, AND OPPORTUNITY, IMMUNOSUPPRESSANTS MARKET
FIGURE 05. COMPARATIVE SHARE ANALYSIS OF IMMUNOSUPPRESANTS MARKET FOR ORGAN TRANSPLANTATION, BY COUNTRY, 2018 & 2026 (%)
FIGURE 06. COMPARATIVE SHARE ANALYSIS OF IMMUNOSUPPRESSANT MARKET FOR AUTOIMMUNE DISORDERS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 07. COMPARATIVE SHARE ANALYSIS OF IMMUNOSUPPRESSANTS MARKET FOR OTHERS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 08. COMPARATIVE SHARE ANALYSIS OF CALCINEURIN INHIBITORS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 09. COMPARATIVE SHARE ANALYSIS OF CORTICOSTEROIDSS IMMUNOSUPPRESSANT MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 10. COMPARATIVE SHARE ANALYSIS OF MONOCLONAL ANTIBODIES IMMUNOSUPPRESSANT MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF MTOR INHIBITORS IMMUNOSUPPRESSANT MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF OTHER IMMUNOSUPPRESSANT MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF IMMUNOSUPPRESSANT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2018 & 2026 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF RETAIL PHARMACIES MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF ONLINE PHARMECY MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 16. ABBVIE: NET SALES, 2016–2018 ($MILLION)
FIGURE 17. ABBVIE: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 18. ABBVIE: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 19. ASTELLAS: SALES, 2016–2018 ($MILLION)
FIGURE 20. ASTELLAS: SALES SHARE BY PRODUCTS AND SERVICES, 2018 (%)
FIGURE 21. ASTELLAS: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 22. BMS: NET SALES, 2016–2018 ($MILLION)
FIGURE 23. BMS: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 24. GSK: REVENUE, 2016–2018 ($MILLION)
FIGURE 25. GSK: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 26. GSK: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 27. INTAS: REVENUE, 2016–2018 ($MILLION)
FIGURE 28. INTAS: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 29. J&J: REVENUE, 2016–2018 ($MILLION)
FIGURE 30. J&J: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 31. J&J: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 32. MYLAN: NET SALES, 2016–2018 ($MILLION)
FIGURE 33. MYLAN: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 34. NOVARTIS: NET SALES, 2016–2018 ($MILLION)
FIGURE 35. NOVARTIS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 36. NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 37. PFIZER: REVENUE, 2016–2018 ($MILLION)
FIGURE 38. PFIZER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 39. PFIZER: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 40. SANOFI: NET SALES, 2016–2018 ($MILLION)
FIGURE 41. SANOFI: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 42. SANOFI: REVENUE SHARE BY REGION, 2018 (%)
Immunosuppressants are the drugs that suppress the strength of immune system or drugs that reduce the immune response. These drugs help in making the body less likely to reject a transplanted organ, such as a liver, heart, or kidney. In addition, immunosuppressants are also used to treat autoimmune disorders such as lupus, psoriasis, and rheumatoid arthritis.
The immunosuppressants market is anticipated to witness a steady growth in the future, owing to rise in prevalence of autoimmune disorders across the globe, and rise in adoption of organ transplantation. Further, surge in development of immunosuppressant drugs such as monoclonal antibodies, mTOR inhibitors, and anti-proliferative agents further propel the market growth. However, side effects of these drugs, such as these drugs make immune system weaker, and high cost of these drugs is expected to hamper the market growth in the future. On the contrary, continuous focus of researchers toward the development of artificial organs is anticipated to create lucrative opportunities in the near future.
Start reading instantly.
This Report and over 66,966+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Contact Details
Need to talk to an expert? Book your free consultation and let our research experts help you with your needs/problems.
Global Report 
Regional Report
Country Report
Related Report